Walgreens trades on the deal, not the stores
- The WBA thesis is now a merger arbitrage story tied to Sycamore Partners, not a normal operating turnaround.
- The agreed cash payment is $11.45 per share, plus one Divested Asset Proceed Right worth up to $3.00 per share.
- U.S. Retail Pharmacy is still under pressure, with retail sales down 5.3% in the quarter ended May 31, 2025.
- U.S. Healthcare improved, with adjusted EBITDA of $86 million, up $63 million from the prior year quarter.
- The biggest risk is deal failure, because the standalone business still faces weak retail demand and pharmacy margin pressure.
A deal spread with weak backing
Walgreens Boots Alliance is best read as a merger arbitrage position. That means the return depends mostly on whether the Sycamore Partners deal closes and what investors get, not on whether Walgreens fixes its stores before then.
The bull case is simple. The deal closes on the expected terms from the Q3 2025 filing. Shareholders receive $11.45 in cash for each share. They also receive one Divested Asset Proceed Right, or DAP right, which can pay up to $3.00 per share if VillageMD assets are sold for enough value.
The bear case is also simple. If the deal fails because of a vote, regulatory review, financing, or another closing condition, the stock would likely trade on the weak standalone company. That company has shrinking U.S. retail sales, pressured pharmacy economics, and large impairment charges that show past assets were worth less than expected.
There is a timing tension. The internal company record used for this page treats the Sycamore transaction as pending based on the latest loaded filing. A current web check found reports that the deal later closed, so investors should verify the live listing status, deal completion, and any DAP right details before acting.
Prescriptions pay the bills
Walgreens makes money from three areas. U.S. Retail Pharmacy sells prescription drugs and front-of-store goods like beauty, health, personal care, and household items. International includes Boots stores and a German pharmaceutical wholesale business. U.S. Healthcare includes VillageMD, Shields, and CareCentrix.
The old strength is reach. Walgreens has a large store base that makes it easy for people to fill prescriptions near home. That footprint is useful, but it also costs a lot to run. Management has been closing underperforming stores because many locations do not support the long-term profit plan.
The break point is the U.S. retail model. In the quarter ended May 31, 2025, U.S. retail sales fell 5.3%, and comparable retail sales fell 2.4%. Pharmacy sales grew, but the filing says branded drug inflation helped that growth, which is not the same as a clean demand win.
Healthcare services are improving but remain uncertain. U.S. Healthcare posted adjusted EBITDA of $86 million in the May 2025 quarter, up $63 million from the year before. Still, VillageMD has been under strategic review, and past impairment charges show that the healthcare pivot cost more and delivered less than hoped.
What Walgreens sells
Prescription drugs
Walgreens fills prescriptions through retail stores, specialty pharmacy, and home delivery. This is the core traffic driver and the center of the U.S. pharmacy business.
Retail products
Stores sell health, wellness, beauty, personal care, consumables, and general merchandise. This area is weak, with U.S. retail sales down 5.3% in the quarter ended May 31, 2025.
Boots and international pharmacy retail
Boots sells pharmacy-led health and beauty products outside the U.S. The International segment reported sales growth of 7.8%, or 5.9% in constant currency, in the May 2025 quarter.
German pharmaceutical wholesale
Walgreens also distributes pharmaceuticals in Germany. This gives the International segment a wholesale stream beyond Boots stores.
VillageMD primary care
VillageMD provides value-based primary care, where doctors are paid partly for patient outcomes and cost control. Its future matters to the DAP right, but the likely cash value and timing are still open questions.
Shields and CareCentrix
Shields supports specialty pharmacy programs for hospitals, while CareCentrix works in post-acute and home care management. These assets helped U.S. Healthcare adjusted EBITDA improve in the latest quarter.
Mostly U.S. pharmacy
Segment mix uses fiscal 2024 sales from the FY2024 10-K: U.S. Retail Pharmacy $115.8 billion, International $23.6 billion, and U.S. Healthcare $8.3 billion. The mix shows how dependent WBA remains on the pressured U.S. pharmacy and retail business.
What can break the trade
Merger does not close
High impact · Medium oddsThe Q3 2025 10-Q says the merger needs conditions and required regulatory approvals, and those may not be met on time or at all. If the deal fails, investors would likely reprice Walgreens as a weak standalone retailer and pharmacy operator.
DAP right pays little or nothing
Medium impact · Medium oddsThe DAP right can pay up to $3.00 per share, but that depends on future VillageMD asset sales. VillageMD has already been impaired, and the internal view treats the realizable value as an open question.
U.S. retail keeps shrinking
High impact · High oddsThe core U.S. Retail Pharmacy segment remains under stress. In the May 2025 quarter, retail sales fell 5.3%, and comparable retail sales fell 2.4%, hurt by store closures and weaker categories like grocery, household, health and wellness, and beauty.
Pharmacy margins stay squeezed
High impact · Medium oddsWalgreens depends on prescriptions, but the pharmacy model has been under pressure from reimbursement and margin issues. Pharmacy sales can rise because branded drugs cost more, while profit per prescription still stays tight.
More asset impairments
Medium impact · Medium oddsWalgreens recorded large goodwill and asset impairments, including $3.0 billion related to VillageMD and $2.0 billion for U.S. Retail Pharmacy in Q2 2025. These are non-cash charges, but they signal that prior growth plans lost value.
In one breath
Is Walgreens Boots Alliance still a normal stock idea?
In the internal view, no. The main question is whether the Sycamore Partners merger closes on the stated terms, not whether Walgreens can finish a long turnaround as a public company.
What would WBA shareholders receive in the deal?
The Q3 2025 10-Q says shareholders would receive $11.45 per share in cash. They would also receive one DAP right worth up to $3.00 per share, tied to future VillageMD asset monetization.
What is the DAP right?
DAP means Divested Asset Proceed. It is a contingent right that can pay cash later if certain VillageMD assets are sold for enough value, but the timing and final payout are uncertain.
What should investors verify first?
They should verify the current deal status and whether WBA is still publicly traded. A web check found reports that the transaction later closed, while this page follows the latest internal filing record that treated the deal as pending.